Bortezomib 3.5 Mg Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 3.5 mg/vial
Reference Brands: Velcade (USA/EU), Bortenat (India)
Category:
Oncology Cancer Care
Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking proteasomes, the enzyme complexes responsible for breaking down proteins in cells, which leads to cancer cell death. Marketed under the brand name Velcade, it is available as a 3.5 mg/vial powder for injection for intravenous or subcutaneous use. It is an essential drug in modern cancer chemotherapy regimens.
Bortezomib 3.5 mg Injection is available in Injection
and strengths such as 3.5 mg/vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bortezomib 3.5 mg Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bortezomib 3.5 mg Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bortezomib is an important anticancer medicine widely used in the treatment of certain blood-related cancers. It belongs to a class of drugs known as proteasome inhibitors and plays a key role in modern oncology therapy. Bortezomib has been approved for use in the initial treatment of multiple myeloma, often in combination with other medicines such as cyclophosphamide and dexamethasone. It is also used in patients who previously responded to treatment and later experienced a relapse after completing prior therapy.
In addition to multiple myeloma, Bortezomib is approved for the treatment of mantle cell lymphoma in patients who have received at least one prior line of therapy. The medicine works by blocking proteasomes, which are responsible for breaking down proteins inside cells. By inhibiting this process, Bortezomib helps disrupt cancer cell growth and can lead to the death of malignant cells.
Due to its proven clinical effectiveness and established role in cancer treatment protocols, Bortezomib is widely used in oncology centers around the world. It is manufactured by several global pharmaceutical companies and is available in different regulated markets, supporting the treatment of patients with complex hematologic malignancies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing